PROAIR DIGIHALER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROAIR DIGIHALER (PROAIR DIGIHALER).
Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP (cAMP) in bronchial smooth muscle, resulting in bronchodilation.
| Metabolism | Primarily metabolized by conjugation (sulfation) in the gastrointestinal tract and liver; minor CYP450 metabolism. |
| Excretion | Renal: 60-70% of systemically absorbed dose excreted in urine as sulfate conjugate; biliary/fecal: minimal (approximately 10% unchanged); unchanged drug in urine: <2% |
| Half-life | Terminal elimination half-life of albuterol (active ingredient) is 3.8-5.0 hours; clinical context indicates drug is rapidly cleared with no significant accumulation |
| Protein binding | Approximately 10% bound to plasma proteins (primarily albumin) |
| Volume of Distribution | Vd of albuterol is approximately 1.0-4.0 L/kg (mean 2.5 L/kg), indicating extensive distribution into tissues |
| Bioavailability | Inhalation: mean absolute bioavailability from a metered-dose inhaler is approximately 7% of the administered dose, though systemic exposure varies with inhaler technique |
| Onset of Action | Inhalation: onset of bronchodilation occurs within 5-15 minutes |
| Duration of Action | Inhalation: duration of bronchodilation is 3-6 hours, with some effect lasting up to 6 hours as per product labeling |
90 mcg (2 inhalations) via oral inhalation every 4-6 hours as needed for bronchospasm. For exercise-induced bronchospasm, 180 mcg (2 inhalations) 15 minutes before exercise.
| Dosage form | POWDER, METERED |
| Renal impairment | No dose adjustment required for renal impairment. Albuterol is primarily hepatically metabolized and renally excreted as metabolites; however, no specific GFR-based guidelines exist. |
| Liver impairment | No specific dose adjustment recommended for hepatic impairment. Use with caution in severe hepatic impairment due to potential accumulation; monitor for adverse effects. |
| Pediatric use | Children 4-11 years: 90-180 mcg (1-2 inhalations) every 4-6 hours as needed. For exercise-induced bronchospasm: 90-180 mcg 15 minutes before exercise. Weight-based dosing not typically used; follow age-based guidelines. |
| Geriatric use | No specific dose adjustment required. Use lowest effective dose due to potential increased sensitivity and comorbidities. Monitor for tachycardia, tremor, and hypertension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROAIR DIGIHALER (PROAIR DIGIHALER).
| Breastfeeding | Albuterol is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 2.5, but the infant dose is estimated to be less than 1% of the maternal dose. Due to low oral bioavailability, significant infant exposure is unlikely. However, observe the infant for signs of beta-adrenergic stimulation (e.g., tachycardia, irritability). The benefit of maternal asthma control generally outweighs the minimal risk to the breastfed infant. |
| Teratogenic Risk | Albuterol sulfate, the active ingredient in PROAIR DIGIHALER, is generally considered low risk during pregnancy. Animal studies have shown no evidence of teratogenicity at clinically relevant doses. In humans, inhaled beta-agonists are not associated with an increased risk of major congenital malformations. However, maternal asthma exacerbations pose significant risks to the fetus, including preterm birth and low birth weight. Therefore, the benefit of controlled asthma outweighs the theoretical risks. First trimester exposure is not linked to increased malformation rates. Second and third trimester use is considered safe, with no known fetal toxicity at standard doses. No specific teratogenic risk profile by trimester is established. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to albuterol or any component of the product"]
| Precautions | ["Paradoxical bronchospasm with fatal outcomes; discontinue immediately if occurs","Life-threatening asthma exacerbations; need for increased use may indicate worsening asthma","Cardiovascular effects: increased heart rate, hypertension, arrhythmias; use with caution in patients with cardiovascular disorders","Hypokalemia and hyperglycemia; monitor serum potassium and glucose in susceptible patients","Rare anaphylactic reactions","Do not exceed recommended dose; excessive use may lead to death"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal respiratory status, peak expiratory flow, and asthma control symptoms. In pregnancy, assess fetal growth and well-being via ultrasound if asthma is poorly controlled or if exacerbations occur. No specific fetal monitoring required for albuterol therapy alone, but monitoring for maternal heart rate and serum potassium is recommended during high-dose or continuous use. |
| Fertility Effects | No adverse effects on fertility have been reported in animal studies with albuterol. In humans, there is no evidence that inhaled beta-agonists impair fertility. However, uncontrolled asthma may be associated with reduced fertility due to chronic hypoxia. Therefore, maintaining asthma control is recommended for reproductive health. |